Ann Surg:HCC术后复发的原因在此!

2017-01-20 MedSci MedSci原创

放射性未识别(隐匿)肝细胞癌(HCC)的切除与肝内HCC复发的高比率有关。然而,尚不清楚这些复发是否代表未确认的原发性肿瘤的不完全切除还是由于HCC形成的固有生物学倾向而导致的新发肿瘤。近期一项旨在比较了HCC患者的原位肝移植(OLT)术后发生HCC的概率与肝癌肝切除术后肝内复发的概率是否不同。研究者们从器官采集和移植(OPTN)国家数据库中的3696名OLTs、单个移植中心的299名OLTs和肝

放射性未识别(隐匿)肝细胞癌(HCC)的切除与肝内HCC复发的高比率有关。然而,尚不清楚这些复发是否代表未确认的原发性肿瘤的不完全切除还是由于HCC形成的固有生物学倾向而导致的新发肿瘤。

近期一项旨在比较了HCC患者的原位肝移植(OLT)术后发生HCC的概率与肝癌肝切除术后肝内复发的概率是否不同。

研究者们从器官采集和移植(OPTN)国家数据库中的3696名OLTs、单个移植中心的299名OLTs和肝胆癌癌中心的232名部分肝切除术中手术治疗中收集患者、肿瘤和病理学数据。

此项研究结果显示:在OPTN和大量移植中心队列中,分别有37%和42%的患者在移植物病理上具有隐性HCC损伤。在癌症中心患者中,2年复发率为46%,并且74%的复发患者仅肝脏复发。

此项研究得出结论:虽然移植和切除群体不同,隐匿性多灶性是常见的,移植物和部分肝切除术后的早期复发率46%基本相似。这些数据表明非有效性手术切除通常由切除时存在的隐蔽性肝内多灶性引起,而不是残余肝脏具有新发肿瘤的恶性倾向产生的。

原始出处:
Aufhauser DD Jr, Sadot E, Murken DR, Eddinger K, Hoteit M, Abt PL, Goldberg DS, DeMatteo RP, Levine MH. Incidence of Occult Intrahepatic Metastasis in Hepatocellular Carcinoma Treated With Transplantation Corresponds to Early Recurrence Rates After Partial Hepatectomy.Ann Surg. 2017 Jan 12. doi: 10.1097/SLA.0000000000002135.

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1991807, encodeId=9596199180ee8, content=<a href='/topic/show?id=ea25610484f' target=_blank style='color:#2F92EE;'>#术后复发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61048, encryptionId=ea25610484f, topicName=术后复发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62e4433, createdName=zz12341234, createdTime=Sun Jan 22 06:00:00 CST 2017, time=2017-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=173180, encodeId=eb181e3180f8, content=肝移植病人的整个肝脏都已经切除,何来隐匿性肝癌?, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160829/IMG57C3D3E8AADAF5240.jpg, createdBy=3d1516247, createdName=zhang3843347, createdTime=Sun Jan 29 19:05:05 CST 2017, time=2017-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1259485, encodeId=fdc71259485fe, content=<a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8545, encryptionId=2200854517, topicName=HCC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Sun Jan 22 04:00:00 CST 2017, time=2017-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=171811, encodeId=33bf1e181170, content=提供了新视野新思维, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=071c2012037, createdName=wmu姿, createdTime=Sat Jan 21 13:14:18 CST 2017, time=2017-01-21, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1991807, encodeId=9596199180ee8, content=<a href='/topic/show?id=ea25610484f' target=_blank style='color:#2F92EE;'>#术后复发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61048, encryptionId=ea25610484f, topicName=术后复发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62e4433, createdName=zz12341234, createdTime=Sun Jan 22 06:00:00 CST 2017, time=2017-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=173180, encodeId=eb181e3180f8, content=肝移植病人的整个肝脏都已经切除,何来隐匿性肝癌?, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160829/IMG57C3D3E8AADAF5240.jpg, createdBy=3d1516247, createdName=zhang3843347, createdTime=Sun Jan 29 19:05:05 CST 2017, time=2017-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1259485, encodeId=fdc71259485fe, content=<a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8545, encryptionId=2200854517, topicName=HCC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Sun Jan 22 04:00:00 CST 2017, time=2017-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=171811, encodeId=33bf1e181170, content=提供了新视野新思维, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=071c2012037, createdName=wmu姿, createdTime=Sat Jan 21 13:14:18 CST 2017, time=2017-01-21, status=1, ipAttribution=)]
    2017-01-29 zhang3843347

    肝移植病人的整个肝脏都已经切除,何来隐匿性肝癌?

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1991807, encodeId=9596199180ee8, content=<a href='/topic/show?id=ea25610484f' target=_blank style='color:#2F92EE;'>#术后复发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61048, encryptionId=ea25610484f, topicName=术后复发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62e4433, createdName=zz12341234, createdTime=Sun Jan 22 06:00:00 CST 2017, time=2017-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=173180, encodeId=eb181e3180f8, content=肝移植病人的整个肝脏都已经切除,何来隐匿性肝癌?, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160829/IMG57C3D3E8AADAF5240.jpg, createdBy=3d1516247, createdName=zhang3843347, createdTime=Sun Jan 29 19:05:05 CST 2017, time=2017-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1259485, encodeId=fdc71259485fe, content=<a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8545, encryptionId=2200854517, topicName=HCC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Sun Jan 22 04:00:00 CST 2017, time=2017-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=171811, encodeId=33bf1e181170, content=提供了新视野新思维, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=071c2012037, createdName=wmu姿, createdTime=Sat Jan 21 13:14:18 CST 2017, time=2017-01-21, status=1, ipAttribution=)]
    2017-01-22 智智灵药
  4. [GetPortalCommentsPageByObjectIdResponse(id=1991807, encodeId=9596199180ee8, content=<a href='/topic/show?id=ea25610484f' target=_blank style='color:#2F92EE;'>#术后复发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61048, encryptionId=ea25610484f, topicName=术后复发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62e4433, createdName=zz12341234, createdTime=Sun Jan 22 06:00:00 CST 2017, time=2017-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=173180, encodeId=eb181e3180f8, content=肝移植病人的整个肝脏都已经切除,何来隐匿性肝癌?, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160829/IMG57C3D3E8AADAF5240.jpg, createdBy=3d1516247, createdName=zhang3843347, createdTime=Sun Jan 29 19:05:05 CST 2017, time=2017-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1259485, encodeId=fdc71259485fe, content=<a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8545, encryptionId=2200854517, topicName=HCC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Sun Jan 22 04:00:00 CST 2017, time=2017-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=171811, encodeId=33bf1e181170, content=提供了新视野新思维, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=071c2012037, createdName=wmu姿, createdTime=Sat Jan 21 13:14:18 CST 2017, time=2017-01-21, status=1, ipAttribution=)]
    2017-01-21 wmu姿

    提供了新视野新思维

    0

相关资讯

WCIO:地塞米松和福沙吡坦可以降低DEB TACE术后PES风险

根据介入肿瘤学世界会议的报告,对原发性肝癌(HCC)患者进行药物洗脱珠肝动脉化疗栓塞术 (DEB TACE) 前联合使用Decadron和Emend,可以预防患者治疗后的栓塞后综合征。辛辛那提大学介入放射学助理教授Abouelmagd Makramalla博士和同事对71名进行DEB TAC的HCC患者进行了研究。一共涉及113个操作,所有患者在术前通过静脉注射8 mg of Decadron(地

存在HCC史的患者近1/3在接受DAA治疗后复发

据国际肝病大会上的一项报道显示,尽管经直接抗病毒治疗后肝细胞癌很少会发生,但是存在HCC史患者其肝癌复发率为29%。

Clin Cancer Res:GCP3靶向CAR T细胞HCC治疗潜力

2014年10月15日,上海交通大学和第二军医大学等处的研究人员在国际癌症研究领域著名期刊 Clinical Cancer Research 发表了一项最新研究成果,在这项研究中,研究人员开发了GCP3特异性嵌合抗原受体(CAR)T细胞,并探讨它们用于肝细胞癌(HCC)治疗的潜力。研究表明,GPC3靶向CAR T细胞,能够有效地消除GPC3阳性HCC细胞,从而为GPC3阳性HCC提供

Hepatology:他汀类药物可帮助HCV患者降低肝硬化和HCC风险

他汀类药物可延迟慢性丙型肝炎(HCV)患者肝纤维化进展、降低肝细胞性肝癌(HCC)风险。但是最有效的他汀类类型和剂量是什么?研究者进行了一项研究,探究不同类型和剂量的他汀类药物对HCV患者肝纤维化和HCC的影响。研究者通过电子检索的丙肝病毒感染的退伍军人(ERCHIVES)数据库获取了2001-2014年使用抗HCV治疗的所有患者,以及肝硬化和HCC信息。使用累积限定日剂量(cDDD)测定他汀类药

J Hepatol:慢乙肝患者发生了自发性HBsAg清除后,还需要进行HCC监测吗?

很少有人知道,对于获得了自发性HBsAg清除的慢乙肝患者进行肝细胞癌( Hepatocellular carcinoma,HCC)的监测是否有价值。 我们进行了一项回顾性分析,纳入了从1997年到2012年韩国三级医院获得了自发性HBsAg清除的共829例患者(中位年龄:52.3岁;575例男性;98例合并有肝硬化),评估了患者自发生HBsAg清除时HCC的发生率和CU-HCC评分。结

Hepatology:核苷(酸)类似物治疗可降低HBV相关性HCC的复发率

对于不适合手术治疗的肝细胞癌(HCC)患者来说,射频消融(RFA)是用于其治疗的最佳选择,但是应努力降低肿瘤复发的风险。本研究旨在探究核苷(酸)类似物(NA)治疗乙型肝炎病毒(HBV)与RFA治疗后肝癌复发风险之间的关联。研究人员使用2004年7月1日至2012年12月31之间的台湾全民健康保险研究数据,共包括48807名新诊断HBV相关的HCC患者。最后研究人员纳入了850名接受RFA治疗HCC